FDA's approval of Abeona Therapeutics Inc.'s Zevaskyn & $155M PRV sale strengthen financials. Click for my updated look at ...

Oppenheimer raised the firm’s price target on Abeona Therapeutics (ABEO) to $20 from $19 and keeps an Outperform rating on the shares following ...

Headline profit and GAAP EPS of $1.71 for Q2 2025 resulted almost entirely from a one-time asset sale rather than ongoing business operations. Q2 2025 marked the first revenue recognition ($0.4 ...

Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the ...

Vinay Prasad, the top deputy to FDA chief Marty Makary, is out after less than three months at the agency.

On July 29, AscellaHealth announced its successful HUB partnership with Abeona Therapeutics in the pre- and post-launch commercialization of ZEVASKYN (prademagene zamikeracel), which is an FDA ...

7-OH is sold in “fruit-flavored gummies and ice cream cones” that could appeal to children, the FDA said.